| Company/Division name | FUJIFILM Diosynth Biotechnologies U.S.A. |
| Parent company | FUJIFILM Holdings Corporation |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 150 |
| Year reshoring announced: | 2022 |
| Capital investment ($): | 300 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | College Station |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Medical Equipment & Supplies |
| Product(s) reshored | Nvovax coronavirus vaccine, medical devices |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Skilled workforce availability/training, Under-utilized capacity |
| Government Incentive dollar amount: | $1.5 million grant, tate’s Texas Enterprise Fund |
